- Home
- GILT vs AVIR Comparison
GILT vs AVIR Comparison
Compare GILT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILT
- AVIR
- Stock Information
- Founded
- GILT 1987
- AVIR 2012
- Country
- GILT Israel
- AVIR United States
- Employees
- GILT N/A
- AVIR N/A
- Industry
- GILT Radio And Television Broadcasting And Communications Equipment
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- GILT Technology
- AVIR Health Care
- Exchange
- GILT Nasdaq
- AVIR Nasdaq
- Market Cap
- GILT 334.1M
- AVIR 247.5M
- IPO Year
- GILT 1993
- AVIR 2020
- Fundamental
- Price
- GILT $6.11
- AVIR $3.51
- Analyst Decision
- GILT Strong Buy
- AVIR Hold
- Analyst Count
- GILT 2
- AVIR 1
- Target Price
- GILT $8.50
- AVIR $6.88
- AVG Volume (30 Days)
- GILT 475.2K
- AVIR 556.5K
- Earning Date
- GILT 02-24-2025
- AVIR 02-26-2025
- Dividend Yield
- GILT N/A
- AVIR N/A
- EPS Growth
- GILT 17.04
- AVIR N/A
- EPS
- GILT 0.29
- AVIR N/A
- Revenue
- GILT $302,932,000.00
- AVIR N/A
- Revenue This Year
- GILT $18.81
- AVIR N/A
- Revenue Next Year
- GILT $32.32
- AVIR N/A
- P/E Ratio
- GILT $21.19
- AVIR N/A
- Revenue Growth
- GILT 15.14
- AVIR N/A
- 52 Week Low
- GILT $4.04
- AVIR $2.75
- 52 Week High
- GILT $6.66
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- GILT 64.11
- AVIR 62.36
- Support Level
- GILT $5.69
- AVIR $3.19
- Resistance Level
- GILT $6.33
- AVIR $3.32
- Average True Range (ATR)
- GILT 0.19
- AVIR 0.12
- MACD
- GILT -0.01
- AVIR 0.04
- Stochastic Oscillator
- GILT 76.92
- AVIR 94.78
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs) and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).